Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 17/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006673 | 0.83 | MLNR (0.42) | MLNRCYP3A4CYP2D6GHSRFLT3 | |
| SCHEMBL3134335 | 0.82 | CHRM4 (0.38) | MLNRLMNA | |
| SCHEMBL2008610 | 0.80 | MLNR (0.49) | MLNRCYP3A4CYP2D6GHSRLMNA | |
| SCHEMBL2013240 | 0.80 | MLNR (0.69) | MLNRCYP3A4CYP2D6GHSR | |
| Hydrochloric Acid SCHEMBL2003648 | 0.79 | MLNR (0.68) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL2012328 | 0.78 | MLNR (0.44) | MLNRCYP3A4CYP2D6GHSRLMNA | |
| SCHEMBL4648049 | 0.78 | MLNR (0.44) | MLNRCYP3A4CYP2D6GHSRLMNA | |
| SCHEMBL2006917 | 0.78 | MLNR (0.69) | MLNRCYP3A4CYP2D6GHSRFLT3 | |
| SCHEMBL2009575 | 0.76 | HDAC1 (0.42) | — | |
| SCHEMBL2007485 | 0.73 | FNTA (0.45) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964602-B2 | Biaryl compounds useful as agonists of the Gpr38 receptor | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-1960390-B1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LTD (GB) | 2010-07-21 | — | — | EP | disclosed |
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GLAXO GROUP LIMITED | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GPR88, GPR68, GPBAR1 | MLNR 47/4885CYP3A4 1125/4885CYP2D6 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.